Last reviewed · How we verify
Acalabrutinib in combination with BR
BTK inhibitor
BTK inhibitor Used for Chronic lymphocytic leukemia, Mantle cell lymphoma.
At a glance
| Generic name | Acalabrutinib in combination with BR |
|---|---|
| Also known as | Acalabrutinib + BR |
| Sponsor | Acerta Pharma BV |
| Drug class | BTK inhibitor |
| Target | BTK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Acalabrutinib is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a key component in the B-cell receptor signaling complex.
Approved indications
- Chronic lymphocytic leukemia
- Mantle cell lymphoma
Common side effects
- Anemia
- Neutropenia
- Thrombocytopenia
- Diarrhea
- Fatigue
- Muscle spasms
- Nausea
- Vomiting
- Abdominal pain
- Headache
Key clinical trials
- A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (PHASE3)
- A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL (PHASE1)
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib in combination with BR CI brief — competitive landscape report
- Acalabrutinib in combination with BR updates RSS · CI watch RSS
- Acerta Pharma BV portfolio CI